Pharmaceuticals

Lilly launches single-dose vial of Zepbound, expanding access for obese adults

bexib
By bexib 0 Min Read

New vials of Zepbound are available through a new copay pharmacy channel and are priced more than 50% lower than other incretin medications for the treatment of obesity.

You Might Also Like

Pharma Pulse 8/22/24: Tufts University Field Experience Study, Obesity Could Be a Good Thing for Arizona, and More

Does the pharmaceutical company’s blockbuster immunotherapy work for dogs?

Is anyone taking the most expensive medicine in the world?

Study finds AI reduces underdiagnosis in Black patients with common heart failure

Kiberna follows oncology CAR-T cell strategy for ultra-rare autoimmune disease

Share This Article
Previous Article UK digital bank OakNorth approved to sell products and services in US
Next Article BMO Bot powers 3 million customer interactions
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

CFPB imposes a fine of $ 2.5 million in Fintech Wise
Banking
Within the city’s cloud migration strategy
Banking
Allstate that sells group health business nationwide
Insurance
Business clients require banks for Fednow and RTP functions
Banking